Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ciprofloxacin in severe infections.

N Aswapokee1, S Pruksachatvuthi, P Aswapokee

  • 1Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Journal of the Medical Association of Thailand = Chotmaihet Thangphaet
|June 1, 1990
PubMed
Summary

Ciprofloxacin demonstrated a 68% cure rate in severe bacterial infections, including septicemia and P. aeruginosa infections. This fluoroquinolone showed promise for resistant bacteria, with mild side effects in most patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRSA carriage in a tertiary governmental hospital in Thailand: emphasis on prevalence and molecular epidemiology.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2010
Same author

Antimicrobial resistance among respiratory pathogens collected in Thailand during 1999-2000.

Journal of chemotherapy (Florence, Italy)·2002
Same author

Carriage of antibiotic-resistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Efficacy and safety of twice daily administration of cefpirome in the empiric treatment of sepsis.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet·1999
Same author

Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1999
Same author

Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet·1993

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Ciprofloxacin is a potent post-marketing fluoroquinolone with promising in vitro activity and pharmacokinetics.
  • Severe bacterial infections often involve pathogens resistant to conventional antibiotics, necessitating novel treatment options.

Purpose of the Study:

  • To evaluate the efficacy and safety of ciprofloxacin in hospitalized patients with severe bacterial infections.
  • To assess the treatment outcomes in patients with infections caused by resistant organisms.

Main Methods:

  • An open clinical trial was conducted involving 25 hospitalized patients with severe bacterial infections.
  • Ciprofloxacin was administered intravenously initially, followed by an oral form. Patients were evaluated for cure, improvement, relapse, or failure.

Related Experiment Videos

Main Results:

  • Nineteen patients were evaluated, with 23 infections treated; septicemia and P. aeruginosa were most common.
  • An overall cure rate of 68% was achieved, with 2 improvements, 2 relapses/reinfections, and 1 failure.
  • One psychotic attack occurred, necessitating drug discontinuation; other adverse effects were mild and transient.

Conclusions:

  • Ciprofloxacin shows significant promise in treating severe bacterial infections, particularly those caused by resistant pathogens.
  • The drug is generally well-tolerated, with most adverse events being mild and transient.